NCT02024152已完成1 期
Safety, Tolerability and Pharmacokinetics Trial of JDP-205 Injection 10 mg
JDP Therapeutics, Inc.1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2011年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Difference in pharmacokinetics: Difference in AUC
研究概览
简要总结
This study is to investigate the pharmacokinetics (PK) together with the safety and tolerability of JDP-205 at 5 mg and 10 mg intravenous doses and 10 mg intramuscular dose, in comparison to the marketed cetirizine oral product Zyrtec® 10 mg tablets (an OTC product) in healthy male and female volunteers after a single dose administration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female volunteer
- •Volunteer aged of at least 18 years
- •Volunteer with a body mass index (BMI) greater than or equal to 18.50 and below 30.00 kg/m2
- •Non- or ex-smokers; an ex-smoker being defined as someone who completely stopped smoking for at least 12 months before day 1 of this study.
- •Availability for the entire study period
- •Motivated volunteer and absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements; ability to cooperate adequately; ability to understand and observe the instructions of the physician or designee
- •Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without any clinical significance
- •Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination (including the examination of the anterolateral thigh muscles) and/or clinical laboratory evaluations (hematology, biochemistry, ECG and urinalysis)
- •Willingness to adhere to the protocol requirements as evidenced by the informed consent form (ICF) duly read, signed and dated by the volunteer
排除标准
- •Females who are pregnant or are lactating
- •Females of childbearing potential who refuse to use an acceptable contraceptive regimen throughout the entire duration of the study (from the screening visit until study completion)
- •History of significant hypersensitivity to cetirizine or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
- •Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects
- •History of significant gastrointestinal, liver or kidney disease that may affect drug bioavailability
- •Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease
- •Suicidal tendency, history of or disposition to seizures, state of confusion, clinically relevant psychiatric diseases
- •Presence of out-of-range cardiac interval (PR < 110 msec, PR > 200 msec, QRS < 60 msec, QRS >110 msec and QTc > 440 msec) on the screening ECG or other clinically significant ECG abnormalities
- •Known presence of rare hereditary problems of galactose and /or lactose intolerance
- •Maintenance therapy with any drug, or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
- •Any clinically significant illness in the previous 28 days before day 1 of this study
- •Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and St John's Wort), in the previous 28 days before day 1 of this study
- •Use of antihistaminic medication in the previous 7 days before day 1 of this study
- •Any history of tuberculosis and/or prophylaxis for tuberculosis
- •Positive urine screening of ethanol and/or drugs of abuse
- •Positive results to HIV, HBsAg or anti-HCV tests
- •Females who are pregnant according to a positive serum pregnancy test
- •Volunteers who took an Investigational Product (in another clinical trial) or donated 50 mL or more of blood in the previous 28 days before day 1 of this study
- •Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study
研究组 & 干预措施
JDP-205 IV high dose
Experimental
干预措施: JDP-205 IV high dose (Drug)
JDP-205 IV high dose
Experimental
干预措施: JDP-205 IV low dose (Drug)
JDP-205 IV high dose
Experimental
干预措施: JDP-205 IM (Drug)
JDP-205 IV low dose
Experimental
干预措施: JDP-205 IV high dose (Drug)
JDP-205 IV low dose
Experimental
干预措施: JDP-205 IV low dose (Drug)
JDP-205 IV low dose
Experimental
干预措施: JDP-205 IM (Drug)
JDP-205 IM high dose
Experimental
干预措施: JDP-205 IV high dose (Drug)
JDP-205 IM high dose
Experimental
干预措施: JDP-205 IV low dose (Drug)
JDP-205 IM high dose
Experimental
干预措施: JDP-205 IM (Drug)
结局指标
主要结局
Difference in pharmacokinetics: Difference in AUC
时间窗: 36 hours post dose
Differences in pharmacokinetics: difference in Cmax
时间窗: 36 hours pose dose
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
撤回
1 期
A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent SubjectsOpioid Withdrawal (Disorder)Opioid Use DisorderNCT06711640USWM, LLC (dba US WorldMeds)16
已完成
1 期
A Study to Evaluate the Safety and Pharmacokinetics of HH-120 Nasal Spray in Healthy VolunteersCOVID-19NCT05753878Huahui Health62
已完成
1 期
Single Rising Dose Study of BI 135585 XX in Health Asian Male Volunteers.HealthyNCT01291732Boehringer Ingelheim48
已完成
1 期
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male SubjectsHealthyNCT02263976Boehringer Ingelheim101
已完成
2 期
Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's DiseaseMild Cognitive ImpairmentAlzheimer's DiseaseNCT01661673FORUM Pharmaceuticals Inc52